Document is current

Article History

Received: 13 March 2022

Accepted: 8 June 2022

First Online: 21 July 2022

Declarations

:

: NB, MCSR, MCPY, FD, CG, GHB, MCH, AL, RM, AM, JPP, RPR, FR, BU, DU, MV, RR, AM and CC report no conflict of interest. OB reports consulting or lecture fees for Amgen, Aptissen, Biophytis, IBSA, MEDA, Mylan, Novartis, Sanofi, Servier, SMB, TRB Chemedica, UCB, Viatris. EMD reports support from Pfizer, UCB, Lilly and Viatris. NF reports educational grants from Pfizer and Eli Lilly. IKH reports consultancies for Novartis and Abbvie, research grant from Pfizer (paid to institution), all outside of the submitted work. MH reports research grant through institution from Amgen, Radius Health, ViiV Healthcare, BD; lecture fees from Teva and Mylan Pharmaceuticals and consulting fees from UCB. EM reports consultancy or speaking fees for Abiogen, Expanscience, Fidia, Meda-Mylan, Pierre Fabre Labs, Sublimed, TRB Chemedica. JYR reports consulting fees or advisory board participation for IBSA-Genevrier, Mylan, Radius Health and Pierre Fabre, lecturing fees for IBSA-Genevrier, Mylan, Cniel and Dairy Research Council (DRC) and grant support from IBSA-Genevrier, Mylan, Cniel and Radius Health. NV reports participation in advisory boards for Mylan, Fidia, Sanofi-Aventis, Viatris, IBSA.

: This article is a retrospective review. To the authors’ knowledge, the reviewed studies were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: For this retrospective review, formal consent is not required.